Milestone Pharmaceuticals Inc. MIST
We take great care to ensure that the data presented and summarized in this overview for Milestone Pharmaceuticals Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MIST
View all-
Black Rock Inc. New York, NY4.97MShares$11.2 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY2.51MShares$5.64 Million0.03% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA1.45MShares$3.27 Million1.35% of portfolio
-
Alta Fundamental Advisers LLC New York, NY1.43MShares$3.21 Million0.56% of portfolio
-
Bml Capital Management, LLC Zionsville, IN1.14MShares$2.56 Million0.74% of portfolio
-
Morgan Stanley New York, NY969KShares$2.18 Million0.0% of portfolio
-
Simplify Asset Management Inc. New York, NY850KShares$1.91 Million0.03% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A6750KShares$1.69 Million0.0% of portfolio
-
Lion Point Capital, LP New York, NY549KShares$1.23 Million4.51% of portfolio
-
Bleichroeder LP New York, NY500KShares$1.13 Million0.14% of portfolio
Latest Institutional Activity in MIST
Top Purchases
Top Sells
About MIST
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Insider Transactions at MIST
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 11
2025
|
Joseph C Papa |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+50.0%
|
-
|
|
Jul 11
2025
|
Lorenz Muller Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,666
+27.58%
|
-
|
|
Jul 11
2025
|
Joseph Oliveto President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
66,666
+16.11%
|
-
|
|
Jul 11
2025
|
David Bharucha Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
53,333
+45.71%
|
-
|
|
Jul 11
2025
|
Robert James Wills |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+43.48%
|
-
|
|
Jul 11
2025
|
Amit Hasija CFO & EVP of Corp. Development |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+50.0%
|
-
|
|
Jul 11
2025
|
Debra K. Liebert |
BUY
Grant, award, or other acquisition
|
Direct |
16,666
+49.81%
|
-
|
|
Mar 22
2023
|
Rtw Investments, LP > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
1,059,000
-24.54%
|
-
|
|
Dec 05
2022
|
David Bharucha Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
7,000
+41.18%
|
$28,000
$4.69 P/Share
|
|
Dec 01
2022
|
David Bharucha Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+50.0%
|
$12,000
$4.86 P/Share
|
|
Oct 21
2022
|
Debra K. Liebert |
BUY
Open market or private purchase
|
Indirect |
4,000
+50.0%
|
$20,000
$5.26 P/Share
|
|
Oct 20
2022
|
Richard C Pasternak Director |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$50,000
$5.2 P/Share
|
|
Oct 20
2022
|
Debra K. Liebert |
BUY
Open market or private purchase
|
Indirect |
10,000
+50.0%
|
$50,000
$5.29 P/Share
|
|
Oct 19
2022
|
Robert James Wills |
BUY
Open market or private purchase
|
Direct |
15,000
+50.0%
|
$60,000
$4.93 P/Share
|
|
Oct 19
2022
|
Michael John Tomsicek |
BUY
Open market or private purchase
|
Direct |
15,000
+50.0%
|
$75,000
$5.32 P/Share
|
|
Sep 14
2022
|
Debra K. Liebert |
BUY
Other acquisition or disposition
|
Direct |
127
+50.0%
|
-
|
|
Sep 07
2022
|
Rtw Investments, LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,557,346
-26.52%
|
$12,458,768
$8.71 P/Share
|
|
Sep 07
2022
|
Rtw Investments, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,557,346
+26.52%
|
$12,458,768
$8.71 P/Share
|
|
May 31
2022
|
Paul F Truex Director |
BUY
Open market or private purchase
|
Direct |
5,000
+5.76%
|
$25,000
$5.6 P/Share
|
|
May 31
2022
|
Paul F Truex Director |
BUY
Exercise of conversion of derivative security
|
Direct |
76,780
+30.03%
|
$76,780
$1.72 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 403K shares |
|---|